SkybriGHt Registry

A US Multi-center, Prospective, Non-interventional, Long Term, Effectiveness and Safety Study of Patients Treated With Lonapegsomatropin-tcgd

Inclusion Criteria

  • Patients who are on treatment with lonapegsomatropin-tcgd
  • Patients being clinically managed in USA
  • Patients with an appropriate written informed consent/assent as applicable for the age of the patient

Exclusion Criteria

  • Patients participating in any interventional clinical study

For additional study information and for inclusion/exclusion criteria: Healthcare providers may visit ClinicalTrials.gov (NCT05820672).

Learn more Frequently Asked Questions

Ascendis Pharma does not recommend or endorse using its medications in a way that conflicts with FDA-approved labeling.